Technology area: Biotechnology & Pharmaceuticals
9 pending office actions • 4 art units • 6 examiners • 0 of 9 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Amazentis SA has 7 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 5 distinct examiners and 3 distinct art units, showing some repeated assignment across both examiner and technical-unit categories.
VALENROD, YEVGENY is the busiest examiner, with 3 pending actions. That examiner relationship is the clearest point for coordinated review, while the remaining matters require separate attention because the portfolio includes other examiner and art-unit assignments.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 3 (33%) |
| §102 only | 1 (11%) |
| Double-patenting only | 1 (11%) |
| Multi-statute (no §101) | 4 (44%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VALENROD, YEVGENY | 4 | 72.5% | +25.1% |
| SCHLIENTZ, NATHAN W | 1 | 41.3% | -18.8% |
| CORNET, JEAN P | 1 | 41.9% | +47.2% |
| GANGLE, BRIAN J | 1 | 76.8% | +14.6% |
| MOU, LIYUAN | 1 | 43.8% | +59.9% |
| FRITCHMAN, REBECCA M | 1 | 45.6% | +35.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17089448 | Diagnostic Method | FRITCHMAN, REBECCA M | 49d overdue |
| 19052943 | SKIN TREATMENT METHODS | SCHLIENTZ, NATHAN W | — |
| 18687108 | TREATING LONG COVID-19 WITH UROLITHINS | CORNET, JEAN P | — |
| 17284363 | COMBINATION OF AN UROLITHIN WITH AN IMMUNOTHERAPY TREATMENT | MOU, LIYUAN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17089448 | Diagnostic Method | FRITCHMAN, REBECCA M | 49d overdue |
| 18114092 | USES OF UROLITHINS | GANGLE, BRIAN J | 36d overdue |
| 19170782 | ENHANCING AUTOPHAGY OR INCREASING LONGEVITY BY ADMINISTRATION OF UROLITHINS | VALENROD, YEVGENY | 55d |
| 19567925 | ENHANCING AUTOPHAGY OR INCREASING LONGEVITY BY ADMINISTRATION OF UROLITHINS | VALENROD, YEVGENY | — |
| 19311619 | ENHANCING AUTOPHAGY OR INCREASING LONGEVITY BY ADMINISTRATION OF UROLITHINS | VALENROD, YEVGENY | — |
| 18687108 | TREATING LONG COVID-19 WITH UROLITHINS | CORNET, JEAN P | — |
| 18205305 | ENHANCING AUTOPHAGY OR INCREASING LONGEVITY BY ADMINISTRATION OF UROLITHINS | VALENROD, YEVGENY | — |
| 17284363 | COMBINATION OF AN UROLITHIN WITH AN IMMUNOTHERAPY TREATMENT | MOU, LIYUAN | — |
| Art Unit | Apps |
|---|---|
| 1628 | 6 |
| 1611 | 1 |
| 1645 | 1 |
| 1758 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19567925 | ENHANCING AUTOPHAGY OR INCREASING LONGEVITY BY ADMINISTRATION OF UROLITHINS | VALENROD, YEVGENY | 1628 | DP | Non-Final OA | — | Pending | Mar 16, 2026 |
| 19311619 | ENHANCING AUTOPHAGY OR INCREASING LONGEVITY BY ADMINISTRATION OF UROLITHINS | VALENROD, YEVGENY | 1628 | §103 | Non-Final OA | — | Pending | Aug 27, 2025 |
| 19170782 | ENHANCING AUTOPHAGY OR INCREASING LONGEVITY BY ADMINISTRATION OF UROLITHINS | VALENROD, YEVGENY | 1628 | §103 | Non-Final OA | 55d | Pending | Apr 04, 2025 |
| 19052943 | SKIN TREATMENT METHODS | SCHLIENTZ, NATHAN W | 1611 | §102§103§112 | Non-Final OA | — | Pending | Feb 13, 2025 |
| 18687108 | TREATING LONG COVID-19 WITH UROLITHINS | CORNET, JEAN P | 1628 | §103§112 | Non-Final OA | — | Pending | Feb 27, 2024 |
| 18205305 | ENHANCING AUTOPHAGY OR INCREASING LONGEVITY BY ADMINISTRATION OF UROLITHINS | VALENROD, YEVGENY | 1628 | §103 | Final Rejection | — | Pending | Jun 02, 2023 |
| 18114092 | USES OF UROLITHINS | GANGLE, BRIAN J | 1645 | §102 | Final Rejection | 36d overdue | Pending | Feb 24, 2023 |
| 17284363 | COMBINATION OF AN UROLITHIN WITH AN IMMUNOTHERAPY TREATMENT | MOU, LIYUAN | 1628 | §103§112Other | Non-Final OA | — | Pending | Apr 09, 2021 |
| 17089448 | Diagnostic Method | FRITCHMAN, REBECCA M | 1758 | §103§112 | Non-Final OA | 49d overdue | Pending | Nov 04, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAmazentis SA has 9 pending office actions as of October 2026, spread across 4 art units and 6 examiners.
Yevgeny Valenrod has the most, with 4 of Amazentis SA's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
